S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NYSE:BDX

Becton, Dickinson and Stock Forecast, Price & News

$258.75
-3.15 (-1.20 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$258.69
Now: $258.75
$262.36
50-Day Range
$236.45
MA: $250.37
$263.30
52-Week Range
$197.75
Now: $258.75
$286.72
Volume1.59 million shs
Average Volume1.34 million shs
Market Capitalization$75.26 billion
P/E Ratio94.78
Dividend Yield1.27%
Beta0.79
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Becton, Dickinson and logo

MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

64th out of 1,925 stocks

Surgical & Medical Instruments Industry

10th out of 169 stocks

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP07588710
Phone201-847-6800
Employees65,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.12 billion
Cash Flow$17.46 per share
Book Value$81.98 per share

Profitability

Net Income$874 million

Miscellaneous

Market Cap$75.26 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$258.75
-3.15 (-1.20 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Becton, Dickinson and (NYSE:BDX) Frequently Asked Questions

How has Becton, Dickinson and's stock price been impacted by COVID-19 (Coronavirus)?

Becton, Dickinson and's stock was trading at $231.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BDX shares have increased by 11.6% and is now trading at $258.75.
View which stocks have been most impacted by COVID-19
.

Is Becton, Dickinson and a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and in the last twelve months. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Becton, Dickinson and stock.
View analyst ratings for Becton, Dickinson and
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Becton, Dickinson and?

Wall Street analysts have given Becton, Dickinson and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Becton, Dickinson and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Larry J. Merlo's approval rating as Becton, Dickinson and's CEO?

6,978 employees have rated Becton, Dickinson and CEO Larry J. Merlo on Glassdoor.com. Larry J. Merlo has an approval rating of 37% among Becton, Dickinson and's employees. This puts Larry J. Merlo in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Becton, Dickinson and's next earnings date?

Becton, Dickinson and is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Becton, Dickinson and
.

How were Becton, Dickinson and's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) posted its earnings results on Tuesday, November, 10th. The medical instruments supplier reported $2.79 EPS for the quarter, topping analysts' consensus estimates of $2.52 by $0.27. The medical instruments supplier earned $4.78 billion during the quarter, compared to the consensus estimate of $4.48 billion. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The company's revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.31 EPS.
View Becton, Dickinson and's earnings history
.

How often does Becton, Dickinson and pay dividends? What is the dividend yield for Becton, Dickinson and?

Becton, Dickinson and declared a quarterly dividend on Tuesday, November 24th. Stockholders of record on Thursday, December 10th will be paid a dividend of $0.83 per share on Thursday, December 31st. This represents a $3.32 dividend on an annualized basis and a yield of 1.28%. The ex-dividend date is Wednesday, December 9th. This is an increase from Becton, Dickinson and's previous quarterly dividend of $0.79.
View Becton, Dickinson and's dividend history
.

Is Becton, Dickinson and a good dividend stock?

Becton, Dickinson and pays an annual dividend of $3.32 per share and currently has a dividend yield of 1.27%. Becton, Dickinson and has been increasing its dividend for 48 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Becton, Dickinson and is 32.55%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Becton, Dickinson and will have a dividend payout ratio of 24.79% next year. This indicates that Becton, Dickinson and will be able to sustain or increase its dividend.
View Becton, Dickinson and's dividend history.

What guidance has Becton, Dickinson and issued on next quarter's earnings?

Becton, Dickinson and issued an update on its first quarter 2021 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.308-5.308 billion, compared to the consensus revenue estimate of $4.69 billion.

What price target have analysts set for BDX?

14 Wall Street analysts have issued twelve-month price objectives for Becton, Dickinson and's stock. Their forecasts range from $260.00 to $300.00. On average, they expect Becton, Dickinson and's stock price to reach $279.67 in the next year. This suggests a possible upside of 8.1% from the stock's current price.
View analysts' price targets for Becton, Dickinson and
or view Wall Street analyst' top-rated stocks.

Who are some of Becton, Dickinson and's key competitors?

What other stocks do shareholders of Becton, Dickinson and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton, Dickinson and investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), The Walt Disney (DIS), Abbott Laboratories (ABT), Intel (INTC), Verizon Communications (VZ), Cisco Systems (CSCO) and CVS Health (CVS).

Who are Becton, Dickinson and's key executives?

Becton, Dickinson and's management team includes the following people:
  • Mr. Vincent A. Forlenza, Exec. Chairman (Age 67, Pay $2.51M)
  • Mr. Thomas E. Polen Jr., Pres, CEO & Director (Age 47, Pay $2.11M)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 63, Pay $1.4M)
  • Mr. Samrat S. Khichi, Exec. VP of Regulatory & Gov. Affairs and Gen. Counsel (Age 53, Pay $2.19M)
  • Mr. Alberto Mas, Exec. VP & Pres of the Medical Segment (Age 59, Pay $1.15M)
  • Mr. Patrick K. Kaltenbach, Exec. VP & Pres of the Life Sciences Segment (Age 57, Pay $1.95M)
  • Mr. Thomas J. Spoerel, VP, Controller & Chief Accounting Officer (Age 42)
  • Mr. Charles R. Bodner, Sr. VP of Corp. Fin. (Age 49)
  • Dr. John A. DeFord, Exec. VP of R&D and CTO (Age 58)
  • Jerry Flasz, Exec. VP of Global Services & Chief Information Officer

What is Becton, Dickinson and's stock symbol?

Becton, Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

Who are Becton, Dickinson and's major shareholders?

Becton, Dickinson and's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.23%), Boston Trust Walden Corp (0.13%), AMI Asset Management Corp (0.08%), Cacti Asset Management LLC (0.07%), Close Asset Management Ltd (0.05%) and Tandem Investment Advisors Inc. (0.05%). Company insiders that own Becton, Dickinson and stock include Alexandre Conroy, Betty D Larson, Catherine M Burzik, Charles R Bodner, Claire Fraser, James C Lim, Patrick Kaltenbach, Ribo Alberto Mas, Roland Goette, Samrat S Khichi, Simon D Campion, Thomas J Spoerel and Vincent A Forlenza.
View institutional ownership trends for Becton, Dickinson and
.

Which major investors are selling Becton, Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including James Hambro & Partners, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Pioneer Trust Bank N A OR, Candriam Luxembourg S.C.A., First Hawaiian Bank, Pacer Advisors Inc., Huntington National Bank, and AMI Asset Management Corp. Company insiders that have sold Becton, Dickinson and company stock in the last year include Claire Fraser, Patrick Kaltenbach, Roland Goette, Simon D Campion, and Vincent A Forlenza.
View insider buying and selling activity for Becton, Dickinson and
or view top insider-selling stocks.

Which major investors are buying Becton, Dickinson and stock?

BDX stock was bought by a variety of institutional investors in the last quarter, including Galibier Capital Management Ltd., Cardinal Capital Management Inc., Gillespie Robinson & Grimm Inc., Tandem Investment Advisors Inc., Rhenman & Partners Asset Management AB, Kestra Advisory Services LLC, Portland Hill Asset Management Ltd, and Aevitas Wealth Management Inc..
View insider buying and selling activity for Becton, Dickinson and
or or view top insider-buying stocks.

How do I buy shares of Becton, Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Becton, Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $258.75.

How big of a company is Becton, Dickinson and?

Becton, Dickinson and has a market capitalization of $75.26 billion and generates $17.12 billion in revenue each year. The medical instruments supplier earns $874 million in net income (profit) each year or $10.20 on an earnings per share basis. Becton, Dickinson and employs 65,000 workers across the globe.

What is Becton, Dickinson and's official website?

The official website for Becton, Dickinson and is www.bd.com.

How can I contact Becton, Dickinson and?

Becton, Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.